EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI

Tony Mok iD, Pasi A Jänne iD, Makoto Nishio iD, Silvia Novello iD, Martin Reck iD, Conor Steuer iD, Yi-Long Wu iD, Ronan Fougeray iD, Pang-Dian Fan iD, Jie Meng iD, David W Sternberg iD, Stephen Esker und 1 weitere

Future Oncology · 2024-05 · 20 (15) · 969-980

DOI: 10.2217/fon-2023-0602 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, online erschienen am 14.12.2023. Verfasst von Tony Mok und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, State Key Laboratory of Translational Oncology & Chinese University of Hong Kong, Hong Kong, Hong Kong PRC. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Camptothecin, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

After disease progression on EGFR tyrosine kinase inhibitor (TKI) therapy, patients with EGFR-mutated NSCLC who are then treated with platinum-based chemotherapy (PBC) obtain only limited clinical benefit with transient responses. Therapies with greater efficacy and tolerable safety profiles are needed in this setting. The receptor tyrosine kinase HER3 is widely expressed in NSCLC, and increased expression is associated with poor treatment outcomes. In the U31402-A-U102 phase I trial, HER3-DXd showed promising antitumor activity with manageable safety in heavily pre-treated patients with EGFR-mutated NSCLC across a range of tumor HER3 expression levels and EGFR TKI resistance mechanisms. HERTHENA-Lung02 is the first phase III trial to evaluate the safety and efficacy of HER3-DXd versus PBC in patients with progression on a third-generation EGFR TKI. Clinical Trial Registration: NCT05338970 (clinicaltrials.gov); 2021-005879-40 (EudraCT Number). In some patients with non-small-cell lung cancer, changes (or mutations) in the DNA sequence can alter a protein called EGFR and allow tumors to grow and survive. Drugs called EGFR tyrosine kinase inhibitors (EGFR TKIs for short) are used to treat these tumors by interfering with the abnormal EGFR protein. Treatment with these drugs can work well at first, but some tumors never respond, and for tumors that do respond, the cancer eventually becomes resistant to the EGFR TKI and the drug stops working. Platinum-based chemotherapy is often prescribed after an EGFR TKI stops working; however, platinum-based chemotherapy can provide only temporary control of the tumor growth. Most patients with non-small-cell lung cancer have a protein called HER3 on the surface of their tumor cells. A new drug candidate called patritumab deruxtecan (HER3-DXd) finds tumor cells and attaches to the HER3 protein on their surface. HER3-DXd then moves inside the cancer cells, where a novel antitumor payload is released and kills the tumor cells. This article describes the phase III clinical trial HERTHENA-Lung02 (NCT05338970) that compares the benefit of HER3-DXd to platinum-based chemotherapy for patients who have non-small-cell lung cancer with the abnormal EGFR protein and whose disease stopped responding or never responded to EGFR TKI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCamptothecinCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansClinical Trials, Phase III as TopicErbB ReceptorsMutationProtein Kinase Inhibitors

Stichwörter der Autor:innen

EGFR-activating mutationHER3-DXdantibody–drug conjugatenon-small-cell lung cancerpatritumab deruxtecan

Substanzen

Antibodies, Monoclonal, HumanizedCamptothecinEGFR protein, humanErbB Receptorspatritumab deruxtecanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Oncology, State Key Laboratory of Translational Oncology & Chinese University of Hong Kong, Hong Kong, Hong Kong PRC.
  • Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
  • Oncology Department at San Luigi Hospital in Orbassano, University of Turin, 10124 Torino, Italy.
  • Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic, 22927 Grosshansdorf, Germany.
  • Hematology & Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.

ORCID-Profile: Tony Mok, Pasi A Jänne, Makoto Nishio, Silvia Novello, Martin Reck, Conor Steuer, Yi-Long Wu, Ronan Fougeray, Pang-Dian Fan, Jie Meng, David W Sternberg, Helena A Yu

Förderung

  • Daiichi-Sankyo

Zitieren

APA

Mok, T., Jänne, P. A., Nishio, M., Novello, S., Reck, M., Steuer, C., Wu, Y. L., Fougeray, R., Fan, P. D., Meng, J., Sternberg, D. W., Esker, S., & Yu, H. A. (2024). HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI. Future Oncology, 20(15), 969-980. https://doi.org/10.2217/fon-2023-0602

Vancouver

Mok T, Jänne PA, Nishio M, Novello S, Reck M, Steuer C, et al. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI. Future Oncology. 2024;20(15):969-980. doi:10.2217/fon-2023-0602

BibTeX
@article{Mok2024,
  author = {Mok, Tony and Jänne, Pasi A and Nishio, Makoto and Novello, Silvia and Reck, Martin and Steuer, Conor and Wu, Yi-Long and Fougeray, Ronan and Fan, Pang-Dian and Meng, Jie and Sternberg, David W and Esker, Stephen and Yu, Helena A},
  title = {HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI},
  journal = {Future Oncology},
  year = {2024},
  volume = {20},
  number = {15},
  pages = {969--980},
  doi = {10.2217/fon-2023-0602}
}
Kostenlos starten →